The KLHDC9 Knockout HeLa Polyclonal Cells represent a pool of HeLa cells that have undergone CRISPR/Cas9-mediated disruption of the KLHDC9 gene, generating a heterogeneous population with loss-of-function mutations. This polyclonal knockout model provides a valuable tool for studying the role of KLHDC9 within the ubiquitin-proteasome system. The use of a polyclonal format mirrors the genetic diversity often observed in tumor cell populations and allows for the investigation of gene function without the clonal biases inherent in single-cell-derived knockout lines.
The host cell line, HeLa, is an extensively characterized immortalized cell line derived from a human cervical adenocarcinoma. These cells are positive for human papillomavirus type 18 (HPV18) and have been widely employed as a model system for cervical cancer research, as well as for investigating fundamental cellular processes. HeLa cells exhibit robust growth kinetics and are amenable to a wide range of genetic manipulations, making them a workhorse in molecular and cellular biology laboratories.
KLHDC9 functions as a substrate recognition component of the Cullin-3 (CUL3) RING E3 ubiquitin ligase complex, interacting with CUL3, RBX1, and NEDD8. It promotes ubiquitination of target proteins by catalyzing ubiquitin transfer from E2 enzymes, marking them for proteasomal degradation by the 26S proteasome. This process is essential for regulating protein homeostasis, and its dysregulation is implicated in cervical cancer. Although upstream regulators and specific downstream substrates of KLHDC9 remain uncharacterized, this knockout model provides a means to investigate these factors. Representative components of this pathway include CUL3, NEDD8, ubiquitin, the 26S proteasome, E1 activating enzyme, and E2 conjugating enzymes.
Disruption of KLHDC9 in HeLa cells creates a loss-of-function model for dissecting its role in substrate degradation. Given the cervical origin, this system is relevant for studying ubiquitin-dependent proteolysis in tumorigenesis, allowing examination of how KLHDC9 loss affects protein stability, proliferation, and apoptosis.
Researchers can utilize these KLHDC9 knockout HeLa cells in diverse experiments. Applications include substrate identification via cycloheximide chase and in vitro ubiquitination assays, proteasome activity measurements, and flow cytometry for cell cycle or apoptosis. Immunoblotting confirms KLHDC9 knockout, and immunofluorescence can assess target protein localization. These cells serve as a platform for cervical cancer research and drug target validation within the ubiquitin-proteasome pathway. For technical inquiries, contact Ascent Research.
